A recent discussion surrounding New Jersey’s proposed legislation allowing police officers to carry epinephrine auto-injectors has brought attention to a newer form of emergency treatment: neffy®, a needle-free epinephrine nasal spray.
As conversations around emergency response evolve, neffy is being viewed by some as a potential next step in how severe allergic reactions are treated in public settings.
What is neffy®?
neffy is a nasal spray form of epinephrine, the same medication found in EpiPens and similar auto-injectors used to treat anaphylaxis.
Instead of requiring an injection into the thigh, neffy is administered as a spray into the nostril.
It received FDA approval in August 2024 for adults and children weighing at least 33 pounds (15 kg). Like traditional epinephrine devices, it is packaged in two single-use doses in case symptoms persist and a second dose is needed.
Why it’s gaining attention
Anaphylaxis is a fast-moving medical emergency. Symptoms such as airway swelling, difficulty breathing, and a drop in blood pressure can become life-threatening within minutes.
Epinephrine is the primary treatment, but timely administration is critical.
A needle-free option may help reduce hesitation in emergency situations. It also simplifies the process for individuals who may not be familiar or comfortable with injectable devices.
Relevance for first responders
Police officers, EMS personnel, and school staff are often the first to encounter medical emergencies in the community.
Many are already trained to administer medications like naloxone (Narcan), which is also delivered as a nasal spray. Because of this, neffy could fit into existing response protocols with minimal adjustment.
While New Jersey’s current legislation focuses on traditional epinephrine auto-injectors, the emergence of nasal delivery systems may influence future discussions around training and equipment.
Current status
As of April 2026:
- neffy is available in the United States by prescription
- School access programs are being introduced in some areas
- Broader adoption among first responders is still in early stages
Any widespread implementation would depend on policy updates, funding, and training at the state and local levels.
Final thoughts
Epinephrine remains a critical tool in treating severe allergic reactions. Advances in how it is delivered may improve accessibility and ease of use, particularly in high-pressure situations.
As states like New Jersey evaluate how first responders are equipped, innovations such as neffy may become part of the broader conversation around emergency preparedness.
